Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity

Nat Commun. 2015 Aug 6:6:7974. doi: 10.1038/ncomms8974.


Omecamtiv Mecarbil (OM) is a small molecule allosteric effector of cardiac myosin that is in clinical trials for treatment of systolic heart failure. A detailed kinetic analysis of cardiac myosin has shown that the drug accelerates phosphate release by shifting the equilibrium of the hydrolysis step towards products, leading to a faster transition from weak to strong actin-bound states. The structure of the human β-cardiac motor domain (cMD) with OM bound reveals a single OM-binding site nestled in a narrow cleft separating two domains of the human cMD where it interacts with the key residues that couple lever arm movement to the nucleotide state. In addition, OM induces allosteric changes in three strands of the β-sheet that provides the communication link between the actin-binding interface and the nucleotide pocket. The OM-binding interactions and allosteric changes form the structural basis for the kinetic and mechanical tuning of cardiac myosin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation
  • Allosteric Site
  • Animals
  • Cardiac Myosins / chemistry
  • Cardiac Myosins / drug effects*
  • Cell Line
  • Green Fluorescent Proteins
  • Humans
  • Mice
  • Protein Structure, Tertiary
  • Urea / analogs & derivatives*
  • Urea / pharmacology


  • Green Fluorescent Proteins
  • omecamtiv mecarbil
  • Urea
  • Cardiac Myosins

Associated data

  • PDB/4P7H
  • PDB/4PA0